 |
Newsletter: November 8, 2011 |
|
|
News and Product Information
|
|
|
Meetings, Conferences, Exhibitions, Seminars
|

|
PyroGene™ recombinant Factor C (rFC) is an innovative assay method that utilizes recombinant technology for the detection of endotoxin. Recombinant Factor C is a synthetic version of the same enzyme in the LAL cascade that is activated by endotoxin with a fluorescent signal for detection rather than a chromogenic or turbidimetric signal.
Benefits include: | • | Endotoxin specific - recombinant technology eliminates false-positive glucan reactions
| | • | Predictable, reliable assay performance lot-to-lot
| | • | Sustainable resource - no animal utilization
| | • | Comparable to other quantitative LAL methods
| | • | 510(K) submissions have been approved by the FDA using PyroGene™ rFC as a final release test
| | • | Comprehensive FDA Master File
|
|
|

Merck Millipore BioMonitoring
|
BioMonitoring
BioMonitoring is about more than state-of-the-art microbiological testing solutions. At Merck Millipore we also provide regulatory expertise, comprehensive service – and trust. For that one result which is invaluable: safe products. more.. |
|
EZ Vacuum Pump
Designed for microbiology analysis, the EZ Stream™ vacuum pump is a filtration pump that transfers filtration liquids directly to waste. This eliminates the need to use a waste container. more.. |
|
Mycoplasma
MilliPROBE® Real-Time Detection System for Mycoplasma, complete sample and assay protection from contamination. more.. |
|
Sterility Testing
With a broad range of high-quality products, ready-to-use validation protocols, and comprehensive services, Steritest systems offer the complete solution for all your sterility applications. Discover how you can test with the best. more.. |
|
Streamlined Filtration
The Milliflex® portfolio combines products and service that streamline your microbial contamination testing workflow. more.. |
|
|
If you no longer wish to receive this newsletter then: cancel newsletter
Please do send us any comments you have about this newsletter.
|